1-(4-溴苯基)哌嗪结构式
|
常用名 | 1-(4-溴苯基)哌嗪 | 英文名 | 1-(4-Bromophenyl)piperazine |
|---|---|---|---|---|
| CAS号 | 66698-28-0 | 分子量 | 241.128 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | 353.3±27.0 °C at 760 mmHg | |
| 分子式 | C10H13BrN2 | 熔点 | 93-94ºC | |
| MSDS | 中文版 美版 | 闪点 | 167.5±23.7 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
| 中文名 | 1-(4-溴苯基)哌嗪 |
|---|---|
| 英文名 | 1-(4-Bromophenyl)piperazine |
| 英文别名 | 更多 |
| 密度 | 1.4±0.1 g/cm3 |
|---|---|
| 沸点 | 353.3±27.0 °C at 760 mmHg |
| 熔点 | 93-94ºC |
| 分子式 | C10H13BrN2 |
| 分子量 | 241.128 |
| 闪点 | 167.5±23.7 °C |
| 精确质量 | 240.026199 |
| PSA | 15.27000 |
| LogP | 1.88 |
| InChIKey | PJHPFAFEJNBIDC-UHFFFAOYSA-N |
| SMILES | Brc1ccc(N2CCNCC2)cc1 |
| 蒸汽压 | 0.0±0.8 mmHg at 25°C |
| 折射率 | 1.575 |
| 储存条件 | 2-8°C |
| 符号 |
GHS07 |
|---|---|
| 信号词 | Warning |
| 危害声明 | H302 + H312 + H332 |
| 警示性声明 | P280 |
| 危害码 (欧洲) | Xi |
| 风险声明 (欧洲) | 20/21/22 |
| 危险品运输编码 | NONH for all modes of transport |
| 海关编码 | 2933599090 |
|
~74%
1-(4-溴苯基)哌嗪 66698-28-0 |
| 文献:Konstantinova, Igor; Bukhryakov, Konstantin; Gezentsvey, Yuri; Krasavin, Mikhail Letters in Organic Chemistry, 2011 , vol. 8, # 9 p. 628 - 630 |
|
~%
1-(4-溴苯基)哌嗪 66698-28-0 |
| 文献:Tetrahedron Letters, , vol. 54, # 3 p. 213 - 216 |
|
~%
1-(4-溴苯基)哌嗪 66698-28-0 |
| 文献:Collection of Czechoslovak Chemical Communications, , vol. 6, p. 211,218 |
| 1-(4-溴苯基)哌嗪上游产品 4 | |
|---|---|
| 1-(4-溴苯基)哌嗪下游产品 6 | |
| 海关编码 | 2933599090 |
|---|---|
| 中文概述 | 2933599090. 其他结构上有嘧啶环的化合物(包括其他结构上有哌嗪环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC-MS, IR and NMR.
J. Pharm. Biomed. Anal. 117 , 325-32, (2015) The current study reports the development and validation of a stability-indicating reversed phase HPLC method for the separation and identification of potential impurities in vortioxetine, a recently ... |
| 1-(4-Bromophenyl)piperazine |
| MFCD00130198 |